Advancement of targeted agents in the treatment of anaplastic thyroid carcinoma / 国际肿瘤学杂志

ABSTRACT

Anaplastic thyroid carcinoma (ATC) is very rare and aggressive in humans,and its survival time is most often expressed in weeks or months.For now,there is no standard treatment for long-term survival,even if the multidisciplinary approach could prolong survival in some patients.The development of oncomolecular biology promotes the understanding about the pathogenesis of ATC from genetic level,and then providing a theoretical basis for targeted therapy.Some targeted drugs have been approved for the treatment of refractory advanced differentiated thyroid cancer,in the meantime,the clinical trials of targeted therapy bring new hope for ATC patients.